379 related articles for article (PubMed ID: 27892653)
21. Human CD56
Amand M; Iserentant G; Poli A; Sleiman M; Fievez V; Sanchez IP; Sauvageot N; Michel T; Aouali N; Janji B; Trujillo-Vargas CM; Seguin-Devaux C; Zimmer J
Front Immunol; 2017; 8():699. PubMed ID: 28674534
[TBL] [Abstract][Full Text] [Related]
22. The Increased Ratio of Blood CD56
Ming B; Wu T; Cai S; Hu P; Tang J; Zheng F; Ye C; Dong L
J Immunol Res; 2020; 2020():7523914. PubMed ID: 32695834
[TBL] [Abstract][Full Text] [Related]
23. The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.
Harlin H; Hanson M; Johansson CC; Sakurai D; Poschke I; Norell H; Malmberg KJ; Kiessling R
J Immunol; 2007 Oct; 179(7):4513-9. PubMed ID: 17878347
[TBL] [Abstract][Full Text] [Related]
24. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts.
Chan A; Hong DL; Atzberger A; Kollnberger S; Filer AD; Buckley CD; McMichael A; Enver T; Bowness P
J Immunol; 2007 Jul; 179(1):89-94. PubMed ID: 17579025
[TBL] [Abstract][Full Text] [Related]
25. Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: Reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity.
Phan MT; Chun S; Kim SH; Ali AK; Lee SH; Kim S; Kim SH; Cho D
Hum Immunol; 2017 Feb; 78(2):103-112. PubMed ID: 27884732
[TBL] [Abstract][Full Text] [Related]
26. Evidence for NK cell subsets based on chemokine receptor expression.
Berahovich RD; Lai NL; Wei Z; Lanier LL; Schall TJ
J Immunol; 2006 Dec; 177(11):7833-40. PubMed ID: 17114454
[TBL] [Abstract][Full Text] [Related]
27. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation.
Romagnani C; Juelke K; Falco M; Morandi B; D'Agostino A; Costa R; Ratto G; Forte G; Carrega P; Lui G; Conte R; Strowig T; Moretta A; Münz C; Thiel A; Moretta L; Ferlazzo G
J Immunol; 2007 Apr; 178(8):4947-55. PubMed ID: 17404276
[TBL] [Abstract][Full Text] [Related]
28. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
29. Natural Killer and Natural Killer T Cells in Juvenile Systemic Lupus Erythematosus: Relation to Disease Activity and Progression.
Zahran AM; Abdel-Rahim MH; Elsayh KI; Hassanien MM; Mahran SA; Hetta HF
Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):161-169. PubMed ID: 30944972
[TBL] [Abstract][Full Text] [Related]
30. Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy.
Rethacker L; Roelens M; Bejar C; Maubec E; Moins-Teisserenc H; Caignard A
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810032
[TBL] [Abstract][Full Text] [Related]
31. CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer.
Gogali F; Paterakis G; Rassidakis GZ; Liakou CI; Liapi C
Thyroid; 2013 Dec; 23(12):1561-8. PubMed ID: 23721357
[TBL] [Abstract][Full Text] [Related]
32. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
Bochem J; Zelba H; Amaral T; Spreuer J; Soffel D; Eigentler T; Wagner NB; Uslu U; Terheyden P; Meier F; Garbe C; Pawelec G; Weide B; Wistuba-Hamprecht K
PLoS One; 2019; 14(8):e0221301. PubMed ID: 31419253
[TBL] [Abstract][Full Text] [Related]
33. Increased Peripheral NKG2A-NKG2D+CD3-CD16+CD56dim NK Cell Subset Was Positively Correlated with Antiphospholipid Antibodies in Patients of Obstetric Antiphospholipid Syndrome.
Zhang Y; Zhao Y; Si W; Yang B; Lin M; Zheng J; Cui L
Immunol Invest; 2022 Feb; 51(2):425-437. PubMed ID: 33103514
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
35. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
36. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
[TBL] [Abstract][Full Text] [Related]
37. Impaired circulating CD56
Jiang Y; Chen Y; Chen L; Yao W; Guan J; Liu X; Wei X; Lin X
Hum Immunol; 2020 Jan; 81(1):32-40. PubMed ID: 31735440
[TBL] [Abstract][Full Text] [Related]
38. CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells.
Vukicevic M; Chalandon Y; Helg C; Matthes T; Dantin C; Huard B; Chizzolini C; Passweg J; Roosnek E
Eur J Immunol; 2010 Nov; 40(11):3246-54. PubMed ID: 20957748
[TBL] [Abstract][Full Text] [Related]
39. An increase in the absolute count of CD56dimCD16+CD69+ NK cells in the peripheral blood is associated with a poorer IVF treatment and pregnancy outcome.
Thum MY; Bhaskaran S; Abdalla HI; Ford B; Sumar N; Shehata H; Bansal AS
Hum Reprod; 2004 Oct; 19(10):2395-400. PubMed ID: 15319390
[TBL] [Abstract][Full Text] [Related]
40. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
